{"id":56222,"date":"2023-04-26T07:03:03","date_gmt":"2023-04-26T05:03:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/"},"modified":"2023-04-26T07:03:03","modified_gmt":"2023-04-26T05:03:03","slug":"alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/","title":{"rendered":"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study"},"content":{"rendered":"
\n

\nThe trial confirms ALE.F02\u2019s good safety profile, exposure and target biological activity<\/i><\/p>\n

BASEL, Switzerland–(BUSINESS WIRE)–Alentis Therapeutics (\u201cAlentis\u201d), the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced results from the multiple-ascending dose (MAD) part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1).<\/p>\n

<\/a><\/p>\n

\nThe trial enrolled 24 subjects: 18 received the active drug and six received placebo across three dose levels. Participants were dosed every two weeks.<\/p>\n

\nDr. Luigi Manenti, Chief Medical Officer<\/b> at Alentis said: \u201cThis study is the first to target CLDN1 in humans. ALE.F02 showed good safety and tolerability at multiple dose levels. There were no serious events and no dose delays or reductions.\u201d Dr. Manenti added that the pharmacokinetics data confirmed the desired exposures, specifically, that the concentrations required for extracellular remodeling were achieved.<\/p>\n

\nSpeaking to the pharmacodynamics, Dr. Manenti said, \u201cWe not only confirmed the evidence of on-target biological activity that we witnessed in our single-ascending dose (SAD) study last June, but we also saw this enriched in the MAD part of the trial.\u201d<\/p>\n

\n\u201cWe achieved what we set out to do in both the SAD and MAD studies,\u201d said Dr. Roberto Iacone, CEO <\/b>of Alentis Therapeutics. \u201cThe successful conclusion of this trial validates that Claudin-1 is a safe target. With ALE.F02 being safe and well tolerated, Alentis can progress platform and indication expansion. This puts us in a strong position as we advance to the next phase of development starting with first-in-patient liver and renal studies this year.\u201d<\/p>\n

\nAbout Alentis Therapeutics
\n
<\/b>Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors with immune evasive properties and fibrotic disease across multiple organs.
\n
Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel\u2019s pharma-biotech hub in Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US.
\n
Visit https:\/\/alentis.ch<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information please contact:<\/b>
Alentis Therapeutics
\n
Nathalie Graf-Tschupp
\n
info@alentis.ch<\/a><\/p>\n

O public relations GmbH
\n
O\u2019Patrick Wilson
\n
o@os-pr.com<\/a>
Tel: +41 (0) 78 888 4332<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The trial confirms ALE.F02\u2019s good safety profile, exposure and target biological activity BASEL, Switzerland–(BUSINESS WIRE)–Alentis Therapeutics (\u201cAlentis\u201d), the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced results from the multiple-ascending dose (MAD) part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1). The trial enrolled 24 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56222","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The trial confirms ALE.F02\u2019s good safety profile, exposure and target biological activity BASEL, Switzerland–(BUSINESS WIRE)–Alentis Therapeutics (\u201cAlentis\u201d), the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced results from the multiple-ascending dose (MAD) part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1). The trial enrolled 24 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T05:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230425005701\/en\/1773566\/21\/Logo_Alentis_RZ_CMYK_gross.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study\",\"datePublished\":\"2023-04-26T05:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/\"},\"wordCount\":433,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005701\\\/en\\\/1773566\\\/21\\\/Logo_Alentis_RZ_CMYK_gross.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/\",\"name\":\"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005701\\\/en\\\/1773566\\\/21\\\/Logo_Alentis_RZ_CMYK_gross.jpg\",\"datePublished\":\"2023-04-26T05:03:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005701\\\/en\\\/1773566\\\/21\\\/Logo_Alentis_RZ_CMYK_gross.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005701\\\/en\\\/1773566\\\/21\\\/Logo_Alentis_RZ_CMYK_gross.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/","og_locale":"en_US","og_type":"article","og_title":"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study - Pharma Trend","og_description":"The trial confirms ALE.F02\u2019s good safety profile, exposure and target biological activity BASEL, Switzerland–(BUSINESS WIRE)–Alentis Therapeutics (\u201cAlentis\u201d), the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced results from the multiple-ascending dose (MAD) part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1). The trial enrolled 24 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-26T05:03:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230425005701\/en\/1773566\/21\/Logo_Alentis_RZ_CMYK_gross.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study","datePublished":"2023-04-26T05:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/"},"wordCount":433,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005701\/en\/1773566\/21\/Logo_Alentis_RZ_CMYK_gross.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/","url":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/","name":"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005701\/en\/1773566\/21\/Logo_Alentis_RZ_CMYK_gross.jpg","datePublished":"2023-04-26T05:03:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230425005701\/en\/1773566\/21\/Logo_Alentis_RZ_CMYK_gross.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230425005701\/en\/1773566\/21\/Logo_Alentis_RZ_CMYK_gross.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56222"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56222\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}